Erasca (ERAS) Return on Capital Employed (2021 - 2026)
Erasca's (ERAS) quarterly Return on Capital Employed came in at 72.93% in Q1 2026, down 3470.0% YoY from 2.16% in Q1 2025, and down 96.55% on a QoQ basis from 37.1% in Q4 2025.
Erasca (ERAS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Erasca (ERAS) has 6 years of Return on Capital Employed data on file, last reported at 72.93% in Q1 2026.
- Quarterly Return on Capital Employed fell 3470.0% year-over-year to 72.93% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 72.93% (down 3470.0% YoY) and the FY2025 annual result came in at 33.48%, up 953.0% from the prior year.
- Return on Capital Employed declined to 72.93% in Q1 2026, from 37.1% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 30.36% in Q1 2022 to a low of 72.93% in Q1 2026.
- A 5-year average of 43.36% and a median of 37.13% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 2519 bps — and 2026, when it sank 3470 bps.
- Tracing ERAS's Return on Capital Employed over 5 years: stood at 57.28% in 2022, then surged by 35 bps to 37.13% in 2023, then rose by 0 bps to 37.08% in 2024, then fell by 0 bps to 37.1% in 2025, then sank by 97 bps to 72.93% in 2026.
- The last three Return on Capital Employed figures came in at 72.93% (Q1 2026), 37.1% (Q4 2025), and 35.63% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | -73.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -73.01% |
| Mar 31, 2026 | -72.93% |
| Dec 31, 2025 | -37.10% |
| Sep 30, 2025 | -35.63% |
| Jun 30, 2025 | -34.11% |
| Mar 31, 2025 | -38.22% |
| Dec 31, 2024 | -37.08% |
| Sep 30, 2024 | -35.74% |
| Jun 30, 2024 | -41.41% |
| Mar 31, 2024 | -40.68% |
| Dec 31, 2023 | -37.13% |
| Sep 30, 2023 | -60.93% |
| Jun 30, 2023 | -57.57% |
| Mar 31, 2023 | -53.25% |
| Dec 31, 2022 | -57.28% |
| Sep 30, 2022 | -33.60% |
| Jun 30, 2022 | -34.15% |
| Mar 31, 2022 | -30.36% |
| Dec 31, 2021 | -25.72% |
| Sep 30, 2021 | -46.40% |